Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler

Commentary: Healthcare Reform is Ruled Constitutional

Jun 29, 2012

In a 5–4 vote, the Supreme Court has ruled in favor of the Constitutionality of the Affordable Care Act.

Congress Move Promptly to Finalize FDA User Fees

Jun 20, 2012

Legislation fails to establish national track-and-trace system, but tackles shortages.

Manufacturers Back Innovation Initiatives

New legislation, government programs aim to bolster drug discovery and reduce regulatory hurdles.
Jun 2, 2012

New legislation, government programs aim to bolster drug discovery and reduce regulatory hurdles.

FDA Explores Options to Expand Access to Non-Rx Drugs

Manufacturers seek clear path to develop safe-use approaches for more risky OTC therapies.
May 2, 2012

Manufacturers seek clear path to develop safe-use approaches for more risky OTC therapies.

Manufacturers Wrestle with Drug Abuse and Shortages

Soaring opioid use creates challenges for new drug development and supply-chain control.
Apr 2, 2012

Soaring opioid use creates challenges for new drug development and supply-chain control.

Communications Advances Present Manufacturer Challenges

Social media use raises questions about applying old standards to new information technology.
Mar 2, 2012

Social media use raises questions about applying old standards to new information technology.

FDA and Justice Department Address Drug Quality Concerns

More collaboration and expanded oversight aim to compel manufacturers to follow GMPs.
Feb 2, 2012

More collaboration and expanded oversight aim to compel manufacturers to follow GMPs.

Budget Crunch, Political Battles Shape Policy Agenda for Year

Pressure to approve new user fees opens the door to action on drug shortages, prices, and regulation.
Jan 2, 2012

Pressure to approve new user fees opens the door to action on drug shortages, prices, and regulation.

FDA Revamps to Meet New Challenges

Added responsibilities and outside concerns prompt overhaul of agency's structure.
Dec 2, 2011

Added responsibilities and outside concerns prompt overhaul of agency's structure.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here